HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
SGP is up 5.02% today. Volume is 89.4K vs a 30-day average of 120.2K (0.74x).
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.

Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering dro…
SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for p…